Non-high-density lipoproteins cholesterol and cardiometabolic diseases
-
Published:2024-07-05
Issue:2
Volume:20
Page:183-194
-
ISSN:2949-3633
-
Container-title:Ateroscleroz
-
language:
-
Short-container-title:jour
Author:
Kashirina A. P.1ORCID, Simonova G. I.1ORCID
Affiliation:
1. Research Institute of Internal and Preventive Medicine –
Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Abstract
At the present stage, non-high-density lipoprotein cholesterol (non-HDL-C) is intensively studied as a predictor of mortality from cardiovascular diseases. An increase in non-HDL-C content is associated with insulin resistance, which is a pathogenetic factor in the development of atherogenic (mixed) dyslipidemia, which is typical for people with metabolic syndrome (MS) and type 2 diabetes mellitus (TDM2). This review analyzes trends in non-HDL-C level since 1985 in foreign countries and in the Russian Federation. Based on the results of international epidemiological studies, conclusions are substantiated about the possibility of predicting the risk of developing MS and type 2 diabetes using the non-HDL-C. The necessity of conducting prospective cohort studies in the Russian population aimed at assessing the role of non-HDL-C in the early diagnosis of MS and TDM2 is shown. The search for literary sources in the electronic information databases eLIBRARY.RU and PubMed. The analysis included studies published from 1990 to 2023.
Publisher
The Institute of Internal and Preventive Medicine
Reference47 articles.
1. Ng M., Fleming T., Robinson M, Thomson B., Graetz N., Margono C., Mullany E.C., Biryukov S., Abbafati C., Abera S.F., Abraham J.P., Abu-Rmeileh N.M., Achoki T., AlBuhairan F.S., Alemu Z.A., Alfonso R., Ali M.K., Ali R., Guzman N.A., Ammar W., Anwari P., Banerjee A., Barquera S., Basu S., Bennett D.A., Bhutta Z., Blore J., Cabral N., Nonato I.C., Chang J.C., Chowdhury R., Courville K.J., Criqui M.H., Cundiff D.K., Dabhadkar K.C., Dandona L., Davis A., Dayama A., Dharmaratne S.D., Ding E.L., Durrani A.M., Esteghamati A., Farzadfar F., Fay D.F., Feigin V.L., Flaxman A., Forouzanfar M.H., Goto A., Green M.A., Gupta R., Hafezi-Nejad N., Hankey G.J., Harewood H.C., Havmoeller R., Hay S., Hernandez L., Husseini A., Idrisov B.T., Ikeda N., Islami F., Jahangir E., Jassal S.K., Jee S.H., Jeffreys M., Jonas J.B., Kabagambe E.K., Khalifa S.E., Kengne A.P., Khader Y.S., Khang Y.H., Kim D., Kimokoti R.W., Kinge J.M., Kokubo Y., Kosen S., Kwan G., Lai T., Leinsalu M., Li Y., Liang X., Liu S., Logroscino G., Lotufo P.A., Lu Y., Ma J., Mainoo N.K., Mensah G.A., Merriman T.R., Mokdad A.H., Moschandreas J., Naghavi M., Naheed A., Nand D., Narayan K.M., Nelson E.L., Neuhouser M.L., Nisar M.I., Ohkubo T., Oti S.O., Pedroza A., Prabhakaran D., Roy N., Sampson U., Seo H., Sepanlou S.G., Shibuya K., Shiri R., Shiue I., Singh G.M., Singh J.A., Skirbekk V., Stapelberg N.J., Sturua L., Sykes B.L., Tobias M., Tran B.X., Trasande L., Toyoshima H., van de Vijver S., Vasankari T.J., Veerman J.L., Velasquez-Melendez G., Vlassov V.V., Vollset S.E., Vos T., Wang C., Wang X., Weiderpass E., Werdecker A., Wright J.L., Yang Y.C., Yatsuya H., Yoon J., Yoon S.J., Zhao Y., Zhou M., Zhu S., Lopez A.D., Murray C.J., Gakidou E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014; 384 (9945): 766–781. doi: 10.1016/S0140-6736(14)60460-8 2. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Sazonova D.V., Mokrysheva N.G. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus, 2023; 26 (2): 104–123. (In Russ.). doi: 10.14341/DM13035 3. Sampson U.K., Fazio S., Linton M.F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr. Atheroscler. Rep., 2012; 14 (1): 1–10. doi: 10.1007/s11883-011-0219-7 4. Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr. Metab. Cardiovasc. Dis., 2013; 23 (9): 799–807. doi: 10.1016/j.numecd.2013.05.002 5. Behbodikhah J., Ahmed S., Elyasi A., Kasselman L.J., de Leon J., Glass A.D., Reiss A.B. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites, 2021; 11 (10): 690. doi: 10.3390/metabo11100690
|
|